# Sincere Capital

> Sincere Capital is a VC fund backing Biotechnology and Pharmaceutical. See 15 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Shanghai, China
- Total investments: 15
- Last investment: Jun 2026
- Lead investor: 27%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/%E4%B8%8A%E6%B5%B7%E4%BF%A1%E7%86%B9%E6%8A%95%E8%B5%84%E7%AE%A1%E7%90%86%E6%9C%89%E9%99%90%E5%85%AC%E5%8F%B8/
- Website: http://www.sincere-capital.com/

Sincere Capital is a VC fund in Shanghai focused on Biotechnology and Pharmaceutical. Sincere Capital, which was founded by senior investment specialists and had completed all the necessary regulatory registration procedures with Asset Management Association of China, mainly engages in investing in the fields of technology innovation and State-Owned Enterprises (SOE) reforms.

## Contacts

5 contacts available for Sincere Capital. Shizune tracks 4 team members at Sincere Capital. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/sincere-capital?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Series A | $14M–$279M |
| Series B | $15M–$30M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 5 | 33% |
| Pharmaceutical | 4 | 27% |
| Medical | 3 | 20% |
| Biopharma | 3 | 20% |
| Electronics | 3 | 20% |

20 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 6 | 40% |
| Series B | 3 | 20% |
| Seed | 2 | 13% |
| Series C | 2 | 13% |
| Angel | 1 | 7% |

6 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| China | 13 | 87% |
| United States | 1 | 7% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Youjin Lan | Chief Executive Officer | 1 | https://shizune.co/investors/profile/youjin-lan |
| Chen Xi | Executive General Manager | 1 | https://shizune.co/investors/profile/chen-xi-d059 |
| Huang Weiting | Partner | 1 | https://shizune.co/investors/profile/huang-weiting-eee1 |
| Lan Youjin | Managing partner | 1 | https://shizune.co/investors/profile/lan-youjin |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Yoguang Technology | Seetrum is an electronics manufacturing firm that provides advanced spectroscopy chips, AI algorithms, and smart perception solutions. | $14.7M | Series A | Jun 23, 2026 |  |
| XellSmart | Xellsmart develops stem cell treatment solutions for a variety of degenerative diseases for which there are now no clinical treatments. Xellsmart is located in Minhang District, Shanghai, China. | $72.6M | Series C | Apr 01, 2026 |  |
| Spectral Domain Technology | Spectral Domain Technology is a provider of 5G low-orbit broadband terminals, supplying operators, industrial Internet companies, satellite Internet, and government and enterprise customers with ocean communication needs. |  | Series A | Sep 27, 2024 |  |
| Laser Link | Laser Link is a laser communication company that focuses on the development of precision optical-mechanical products for commercial aircraft. | $13.7M | Series A | Nov 10, 2023 |  |
| Zenosic | Zenosic focuses in the design and R&D of high-performance network chips, along with offering leading chip products for cloud service providers, equipment makers, operators, and diverse industries. | $41.9M | Series A | Sep 06, 2023 |  |
| Cullgen | Cullgen is a drug discovery service intended to create new drugs for the treatment of diseases that currently lack effective therapies. The company's services use protein degradation technology that focuses on the selective degradation of disease-causing proteins, a novel treatment for cancer, inflammatory and autoimmune diseases, includingtargets previously considered undruggable, enabling scientists with new means to develop novel therapeutic approaches for various diseases. | $35M | Series C | May 08, 2023 |  |
| Base Therapeutics | Best Bio is a developer of cell therapy products and gene therapy products. |  | Series A | Jan 16, 2023 |  |
| GalaxySpace | GalaxySpace is a commercial micro-satellites developer. |  | Series D | Sep 07, 2022 |  |
| Bichen Pharmaceutical | Bichen Pharmaceutical is a small-molecule tumor-targeted drug developer for the treatment of various malignant tumors and brain metastases. | $30M | Series B | Jan 04, 2022 |  |
| Yoguang Technology | Seetrum is an electronics manufacturing firm that provides advanced spectroscopy chips, AI algorithms, and smart perception solutions. |  | Seed | Dec 29, 2021 |  |

10 of 15 investments shown.

## Co-investors
- [AstraZeneca-CICC Venture Capital](https://shizune.co/investors/profile/astrazeneca-cicc-venture-capital) — VC Fund, 2 deals together
- [Baidu Ventures](https://shizune.co/investors/profile/baidu-ventures) — VC Fund, 2 deals together
- [Highlight Capital](https://shizune.co/investors/profile/highlight-capital-llc) — VC Fund, 2 deals together
- [Anhui Sanzhongyichuang Industry Development](https://shizune.co/investors/profile/anhui-sanzhongyichuang-industry-development) — VC Fund, 1 deal together
- [CCB International](https://shizune.co/investors/profile/ccb-international) — VC Fund, 1 deal together
- [Chaos Investment](https://shizune.co/investors/profile/chaos-investment) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [Chevron Technology Ventures](https://shizune.co/investors/profile/chevron-technology-ventures) — VC Fund
- [Evok Innovations](https://shizune.co/investors/profile/evok-innovations) — VC Fund
- [Scottish Enterprise](https://shizune.co/investors/profile/scottish-enterprise) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [IDG Capital](https://shizune.co/investors/profile/idg-capital-partners) — VC Fund
- [Qiming Venture Partners](https://shizune.co/investors/profile/qiming-venture-partners) — VC Fund
- [HSG](https://shizune.co/investors/profile/sequoia-capital-china) — VC Fund

## Featured in investor lists
- [Oil and Gas VC Funds in Asia](https://shizune.co/investors/oil-and-gas-vc-funds-asia)
- [Oil and Gas Investors in China](https://shizune.co/investors/oil-and-gas-investors-china)
- [Oil and Gas VC Funds in China](https://shizune.co/investors/oil-and-gas-vc-funds-china)

## FAQ

### What does Sincere Capital invest in?

Sincere Capital invests primarily in Biotechnology, Pharmaceutical and Medical startups, most often at Series A and Series B stage. Most of the 15 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Sincere Capital's check size?

Sincere Capital typically joins rounds of $14M–$279M at Series A and $15M–$30M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Sincere Capital participates in.

### How do I contact Sincere Capital?

Public channels for Sincere Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Sincere Capital?

The team at Sincere Capital includes Youjin Lan (Chief Executive Officer), Chen Xi (Executive General Manager) and Huang Weiting (Partner). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co